Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.

Wentink MQ, Hackeng TM, Tabruyn SP, Puijk WC, Schwamborn K, Altschuh D, Meloen RH, Schuurman T, Griffioen AW, Timmerman P.

Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12532-12537. Epub 2016 Oct 17.

2.

GATA2 is required for lymphatic vessel valve development and maintenance.

Kazenwadel J, Betterman KL, Chong CE, Stokes PH, Lee YK, Secker GA, Agalarov Y, Demir CS, Lawrence DM, Sutton DL, Tabruyn SP, Miura N, Salminen M, Petrova TV, Matthews JM, Hahn CN, Scott HS, Harvey NL.

J Clin Invest. 2015 Aug 3;125(8):2979-94. doi: 10.1172/JCI78888. Epub 2015 Jul 27.

3.

Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer.

Bovy N, Blomme B, Frères P, Dederen S, Nivelles O, Lion M, Carnet O, Martial JA, Noël A, Thiry M, Jérusalem G, Josse C, Bours V, Tabruyn SP, Struman I.

Oncotarget. 2015 Apr 30;6(12):10253-66.

4.

MiR-205 is downregulated in hereditary hemorrhagic telangiectasia and impairs TGF-beta signaling pathways in endothelial cells.

Tabruyn SP, Hansen S, Ojeda-Fernández ML, Bovy N, Zarrabeitia R, Recio-Poveda L, Bernabéu C, Martial JA, Botella LM, Struman I.

Angiogenesis. 2013 Oct;16(4):877-87. doi: 10.1007/s10456-013-9362-9. Epub 2013 Jun 26.

5.

MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.

Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, Scherr M, Castermans K, Malvaux L, Lambert V, Thiry M, Sliwa K, Noel A, Martial JA, Hilfiker-Kleiner D, Struman I.

J Clin Invest. 2013 May;123(5):2143-54. doi: 10.1172/JCI64365. Epub 2013 Apr 24.

6.

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.

Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You WK, Chapman HA, Christensen JG, Aftab DT, McDonald DM.

Cancer Discov. 2012 Mar;2(3):270-87. doi: 10.1158/2159-8290.CD-11-0240. Epub 2012 Feb 24.

7.

The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation.

Nguyen NQ, Castermans K, Berndt S, Herkenne S, Tabruyn SP, Blacher S, Lion M, Noel A, Martial JA, Struman I.

PLoS One. 2011;6(11):e27318. doi: 10.1371/journal.pone.0027318. Epub 2011 Nov 7.

8.

Angiopoietin-2-driven vascular remodeling in airway inflammation.

Tabruyn SP, Colton K, Morisada T, Fuxe J, Wiegand SJ, Thurston G, Coyle AJ, Connor J, McDonald DM.

Am J Pathol. 2010 Dec;177(6):3233-43. doi: 10.2353/ajpath.2010.100059. Epub 2010 Oct 15.

9.

Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis.

Sabatel C, Cornet AM, Tabruyn SP, Malvaux L, Castermans K, Martial JA, Struman I.

Mol Cancer. 2010 Sep 2;9:231. doi: 10.1186/1476-4598-9-231.

10.

Angiopoietin/Tie2 signaling transforms capillaries into venules primed for leukocyte trafficking in airway inflammation.

Fuxe J, Lashnits E, O'Brien S, Baluk P, Tabruyn SP, Kuhnert F, Kuo C, Thurston G, McDonald DM.

Am J Pathol. 2010 Apr;176(4):2009-18. doi: 10.2353/ajpath.2010.090976. Epub 2010 Feb 4.

11.

NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents.

Tabruyn SP, Mémet S, Avé P, Verhaeghe C, Mayo KH, Struman I, Martial JA, Griffioen AW.

Mol Cancer Ther. 2009 Sep;8(9):2645-54. doi: 10.1158/1535-7163.MCT-09-0383. Epub 2009 Aug 25.

12.

Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.

Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, McDonald DM.

Cancer Res. 2009 May 15;69(10):4527-36. doi: 10.1158/0008-5472.CAN-08-3779. Epub 2009 Apr 28.

13.

Angiostatic activity of the antitumor cytokine interleukin-21.

Castermans K, Tabruyn SP, Zeng R, van Beijnum JR, Eppolito C, Leonard WJ, Shrikant PA, Griffioen AW.

Blood. 2008 Dec 15;112(13):4940-7. doi: 10.1182/blood-2007-09-113878. Epub 2008 May 30.

14.

NF-kappa B: a new player in angiostatic therapy.

Tabruyn SP, Griffioen AW.

Angiogenesis. 2008;11(1):101-6. doi: 10.1007/s10456-008-9094-4. Epub 2008 Feb 19. Review.

15.

Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL.

Nguyen NQ, Cornet A, Blacher S, Tabruyn SP, Foidart JM, Noël A, Martial JA, Struman I.

Mol Ther. 2007 Dec;15(12):2094-100. Epub 2007 Aug 28.

16.

Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways.

Verhaeghe C, Remouchamps C, Hennuy B, Vanderplasschen A, Chariot A, Tabruyn SP, Oury C, Bours V.

Biochem Pharmacol. 2007 Jun 15;73(12):1982-94. Epub 2007 Mar 24.

PMID:
17466952
17.

A new role for NF-kappaB in angiogenesis inhibition.

Tabruyn SP, Griffioen AW.

Cell Death Differ. 2007 Aug;14(8):1393-7. Epub 2007 Apr 27. No abstract available.

18.

The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation.

Tabruyn SP, Sabatel C, Nguyen NQ, Verhaeghe C, Castermans K, Malvaux L, Griffioen AW, Martial JA, Struman I.

Mol Endocrinol. 2007 Jun;21(6):1422-9. Epub 2007 Apr 3.

19.

Intrinsic pro-angiogenic status of cystic fibrosis airway epithelial cells.

Verhaeghe C, Tabruyn SP, Oury C, Bours V, Griffioen AW.

Biochem Biophys Res Commun. 2007 May 11;356(3):745-9. Epub 2007 Mar 16.

20.

Molecular pathways of angiogenesis inhibition.

Tabruyn SP, Griffioen AW.

Biochem Biophys Res Commun. 2007 Mar 30;355(1):1-5. Epub 2007 Jan 30. Review.

PMID:
17276388
21.

Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis.

Nguyen NQ, Tabruyn SP, Lins L, Lion M, Cornet AM, Lair F, Rentier-Delrue F, Brasseur R, Martial JA, Struman I.

Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14319-24. Epub 2006 Sep 14.

22.

The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases.

Tabruyn SP, Nguyen NQ, Cornet AM, Martial JA, Struman I.

Mol Endocrinol. 2005 Jul;19(7):1932-42. Epub 2005 Mar 3.

23.

The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB.

Tabruyn SP, Sorlet CM, Rentier-Delrue F, Bours V, Weiner RI, Martial JA, Struman I.

Mol Endocrinol. 2003 Sep;17(9):1815-23. Epub 2003 Jun 5.

Supplemental Content

Loading ...
Support Center